V gamma 9 V delta 2 T-cell receptor (Vγ9Vδ2 TCR) (Vγ9Vδ2 TCR)

The Vγ9Vδ2 T-cell receptor (Vγ9Vδ2 TCR) is the defining receptor of the most abundant γδ T-cell subset in human peripheral blood, mediating the non-MHC-restricted recognition of small pyrophosphate intermediates of the mevalonate pathway, known as phosphoantigens (pAg). These pAgs, such as isopentenyl pyrophosphate (IPP), are frequently overproduced in malignant cells due to metabolic dysregulation or in cells infected by certain pathogens (Rigau et al., 2020, Science). The recognition process is uniquely dependent on the butyrophilin family proteins, specifically Butyrophilin 3A1 (BTN3A1) and Butyrophilin 2A1 (BTN2A1), which act as molecular sensors for intracellular pAg levels and undergo conformational changes that are detected by the Vγ9Vδ2 TCR (Karunakaran et al., 2014, Immunity). Therapeutic strategies targeting this axis include the use of aminobisphosphonates to induce pAg accumulation, or novel monoclonal and bispecific antibodies (e.g., ICT01, LAVA-1207) that directly modulate BTN3A1 or bridge the TCR to tumor-associated antigens (Vantourout & Hayday, 2013, Annual Review of Immunology). Because pAg accumulation is a hallmark of metabolic stress in cancer, this target system provides a potent mechanism for the selective immune-mediated destruction of tumor cells while sparing healthy tissues.

Other names

Vgamma9Vdelta2 TCRVg9Vd2 TCRPhosphoantigen-responsive T-cell receptorBTN3A1-phosphoantigen complexVγ9Vδ2 T-cell receptor

Activation of Vγ9Vδ2 T cells through the recognition of intracellular phosphoantigens (pAg) presented by the Butyrophilin 3A1 (BTN3A1) and Butyrophilin 2A1 (BTN2A1) complex on the surface of target cells. Drugs may act by increasing intracellular pAg levels (aminobisphosphonates), stabilizing the active conformation of BTN3A1 (monoclonal antibodies), or directly engaging the TCR (bispecific antibodies).